Prot #N91115-1CF-03 (SNO-4): A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Study of N91115 to Evaluate Safety and Pharmacokinetics in Patients with Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

Project: Research project

Project Details

StatusFinished
Effective start/end date3/4/15 → 3/4/18

Funding

  • Nivalis Therapeutics, Inc. (Prot #N91115-1CF-03 (SNO-4))